The current financial score of Ginkgo Bioworks Holdings Inc is 7.00. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 20.16M, representing a year-over-year decrease of 48.49%, while its net profit experienced a year-over-year decrease of 22.54%.
The current valuation score of Ginkgo Bioworks Holdings Inc is 6.72. Its current P/E ratio is -1.60, which is -81.49% below the recent high of -0.30 and -169.04% above the recent low of -4.32.
The current earnings forecast score of Ginkgo Bioworks Holdings Inc is 4.67. The average price target is 7.00, with a high of 9.00 and a low of 5.00.
The current price momentum score of Ginkgo Bioworks Holdings Inc is 5.61. Currently, the stock price is trading between the resistance level at 10.08 and the support level at 6.80, making it suitable for range-bound swing trading.
The current institutional shareholding score of Ginkgo Bioworks Holdings Inc is 5.00. The latest institutional shareholding proportion is 62.67%, representing a quarter-over-quarter decrease of 24.47%. The largest institutional shareholder is Baillie Gifford, holding a total of 2.39M shares, representing 0.02% of shares outstanding, with 38.46% decrease in holdings.
The current risk assessment score of Ginkgo Bioworks Holdings Inc is 3.44. The company's beta value is 1.80. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.